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Introduction
Hypocalcemia is a known side effect of 
regorafenib, however, the mechanism is 
poorly understood. Regorafenib is a new 
tyrosine kinase inhibitor approved by the US 
Food and Drug Administration (FDA) for 
treatment of metastatic colorectal cancer.1 
This report describes a case of profound 
hypocalcemia potentially related to the use 
of regorafenib in a patient with metastatic 
colon cancer. The etiology of hypocalcemia 
is not clearly published in the English 
literature. This case illustrated the 
importance of monitoring calcium and 
phosphate levels in patients who are on a 
tyrosine kinase inhibitor to avoid potential 
lethal toxicity.  
 
Case Report 
A 65-year-old woman with a history of 
hypertension, diabetes, and metastatic colon 
cancer presented with progressive weakness, 
fatigue, and postictal symptoms at an 
oncology clinic. She had profound hypo-
calcemia (corrected Ca 5.5 mg/dl, baseline 
of 8.3 mg/dl) and was admitted to the 
hospital (see Figure 1 for lab results). She 
recently had been started on regorafenib 
approximately 15 days prior to presentation.  
Her parathyroid hormone (PTH) level 
was elevated at 541 pg/ml (reference 10-65 
pg/ml) and her phosphorus level was 4.5 
mg/dl. Her 25-hydroxy vitamin D level was 
low at 4 ng/ml (reference 30-80ng/ml). 
Urine studies showed a random urine 
calcium less than 2 mg/dl/24-hour. There 
was normal urinary excretion of phosphate, 
sodium, potassium, and cyclic adenosine 
monophosphate (AMP). Her admission 
echocardiogram revealed a prolonged QTc 
of 487 msec. 
On admission, regorafenib was 
discontinued and the patient was admitted to 
the telemetry unit. Her hypocalcemia was 
managed with intravenous calcium infusion 
to maintain serum calcium above 6 mg/dl. 
She required approximately 22 g of calcium 
gluconate infusion over the first four days of 
hospitalization. On day 5 of admission, 
ergocalciferol as well as calcitriol was 
initiated, and she was transitioned from 
parenteral calcium to oral calcium citrate as 
her serum calcium levels improved. On day 
10, her calcium levels stabilized close to 
baseline and she was discharged on calcium 
citrate 3800 mg TID AC, ergocalciferol 
50,000u q48h, and calcitriol 2 mcg PO TID. 
Follow-up laboratory studies demonstrated 
stability of her calcium and phosphorus 
levels.  
 
Discussion 
Regorafenib is a multi-kinase 
inhibitor that targets kinases involved with 
tumor angiogenesis and oncogenesis.2 It 
may cross-react with other receptors 
involved in both calcium and phosphate 
homeostasis. We hypothesized that the 
degree of profound hypocalcemia in our 
patient may have been due to severe vitamin 
D deficiency and possible PTH resistance 
type 2.   
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Figure 1. Serum calcium, albumin, and phosphorus levels over time. 
 
Proposed mechanisms of action for 
regorafenib included: 1) increased 
metabolism of vitamin D in the liver by 
inducing P 450 enzyme activity or inhibiting 
hydroxylation of vitamin D to 25-hydroxy 
vitamin D or 2) induction of PTH resistance 
type 2 in which there is a defect downstream 
on the PTH receptor pathway allowing 
normal levels of urinary cyclic AMP but low 
calcium and Vitamin D levels.3 Profound 
hypocalcemia can have very serious clinical 
consequences. This case suggested that 
serum calcium levels should be monitored 
closely among patients receiving tyrosine 
kinase inhibitor to avoid potential lethal 
toxicity. 
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